Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

<p><strong>Background</strong> The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-...

Detaylı Bibliyografya
Asıl Yazarlar:	Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ
Diğer Yazarlar:	Oxford COVID Vaccine Trial Group
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Elsevier 2021

Benzer Materyaller

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Yazar:: Emary, KRW, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Marchevsky, NG, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Yazar:: Clemens, SAC, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Yazar:: Flaxman, A, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Natalie Gabrielle Marchevsky, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Yazar:: Hillson, K, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Yazar:: Sue Ann Costa Clemens, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Yazar:: Frater, J, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Yazar:: Ramasamy, MN, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
Yazar:: Jeewandara, C, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
Yazar:: Maria da Penha Gomes Gouvea, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
Yazar:: Chandima Jeewandara, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
Yazar:: Swanson, PA, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
Yazar:: Jeewandara, C, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
Yazar:: Chandima Jeewandara, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
Yazar:: Li, G, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
Yazar:: Costa Clemens, SA, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Yazar:: Barrett, J, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
Yazar:: Jeewandara, C, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
Yazar:: Ewer, K, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting
Yazar:: Ridma Prasadini Karunathilake, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
Yazar:: Rapisa Nantanee, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Yazar:: Folegatti, PM, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
Yazar:: Jayathilaka, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) vaccine
Yazar:: Meenakshi Sindhu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
Yazar:: Shu-Hsing Cheng, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study
Yazar:: Debaprasad Parai, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
Yazar:: Suvimol Niyomnaitham, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study
Yazar:: Shahin Soltani, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study
Yazar:: Meeraus, W, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Yazar:: Ramasamy, MN, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
Yazar:: Adam Abdullahi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
Yazar:: Kriangkrai Tawinprai, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY
Yazar:: D. Bhattacharya, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
Yazar:: Michael Müller, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
Yazar:: Zhijie Dai, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Bioethical Crossroads: the Case of the Oxford- AstraZeneca azd1222 Vaccine Against covid-19
Yazar:: Fabio Alberto Garzón Díaz
Baskı/Yayın Bilgisi: (2024-08-01)

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review
Yazar:: George Kroumpouzos, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)